SEATTLE, March 7 /PRNewswire-FirstCall/ --
ENBREL(R) (etanercept) has been on the market since 1998 and under
development for over ten years.
Over at least the past two years, ZymoGenetics has raised their patents
with Immunex, but has never charged Immunex with infringement, even though
Immunex has, on numerous occasions, requested that ZymoGenetics explain their
patent position.
Immunex believes ZymoGenetics' allegations are without merit and will
vigorously defend itself against this lawsuit.
Immunex Corporation is a biopharmaceutical company dedicated to improving
lives through immune system science innovations.
NOTE: Except for the historical information contained herein, this news
release contains forward-looking statements that involve substantial risks and
uncertainties. Among the factors that could cause actual results or timelines
to differ materially are risks associated with research and clinical
development, regulatory approvals, our supply capabilities and reliance on
third-party manufacturers, product commercialization, competition, litigation
and other risk factors listed from time to time in reports filed by Immunex
with the SEC, including but not limited to risks described under the caption
"Important Factors That May Affect Our Business, Our Results of Operations and
Our Stock Price" within our most recently filed Form 10-Q. The forward-
looking statements contained in this news release represent our judgment as of
the date of this release. Immunex undertakes no obligation to publicly update
any forward-looking statements.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/434644.html
CONTACT:
media, Josh Schroeter, +1-206-389-4335, or
investors, Mark Leahy, +1-206-389-4363, both of Immunex
Corporation
|
